Alliance Pharma is presenting in London on the 16th May at the Chesterfield Mayfair Hotel from 6pm. Free to attend. REGISTER HERE: http://www.proactiveinvestors.co.uk/register/event_details/189
21 Mar '13
Solid looking results. Finncap were looking for EPS of 3p this year 2012 and 3.6p year ending 2013 therefore company are 1 year ahead on expected profits. Dividend risen aswel 10%...excelent news. http://www.investegate.co.uk/alliance-pharma-plc--aph-/rns/preliminary-results/201303210700265097A/
15 Mar '13
APH Alliance Pharma. Results on the 21st of this month. Thursday. Think profits will beat broker forecast.. just added.
13 Feb '13
APH Not far off breaking out. BUY placed on it by SCSW tip sheet this weekend. Personaly Im looking for a bolt on before results on 21st of March... see historical item below..... Alliance Pharma gets more ammo for acquisition drive 15th Jan 2013, 1:16 pm by Philip Whiterow Alliance has £13.5mln to spend following the latest injection of funds. Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis. The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln. Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds. Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline. If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts. “P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating,” said Numis. Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol. “As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations,“ the specialist pharmaceutical group said. Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year. Sales were hit by Sanofi Pasteur’s temporary suspension of the manufacture of Immucyst in June, but Hydromol’s record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln. Last year’s acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said. Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update. The company’s business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products. Shares rose by 4% to 33.5p. http://www.proactiveinvestors.co.uk/companies/news/52444/alliance-pharma-gets-more-ammo-for-acquisition-drive-52444.html
22 Oct '12
Alliance Pharma: Investec ups target from 28p to 28.7p, hold rating kept.
19 Oct '12
Alliance Pharma, a speciality pharmaceutical company, has said its wholly owned subsidiary, Alliance Pharmaceuticals, has acquired Opus Group Holdings for £8.0m plus the net asset value of Opus at completion (estimated at £1.5m). The Opus group sells products for stoma care, including skin creams and cleansers, in the UK and Ireland. In the year ended March 31st Opus delivered turnover of £3.8m and pre-tax profit of £2.1m. The consideration is being funded from existing cash and bank facilities.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.